The decline in Novo Nordisk shares is not the result of a single factor, but rather the result of a complex set of fundamental issues: weakening financial performance, loss of competitive advantage in key products, and increased strategic risks.
While negative data on Eli Lilly's weight loss pill in August 2025 triggered a temporary optimistic rebound in NVO shares, it failed to reverse the overall downward trend caused by the company's deeper structural problems.
Now, in order:
Operating and Financial Results
Sales and operating profit growth forecasts for 2025 have been lowered twice; Q3 2025 results below expectations
Operating margin fell to 41.7% from 44.7% (YoY), gross margin decreased to 81.0% from 84.6%
Free cash flow declined 11% due to a sharp increase in capital expenditures
Competitive pressure:
Superiority of Eli Lilly products.
Zepbound (Eli Lilly) demonstrates greater effectiveness in weight loss (20.2% vs. 13.7% for Wegovy); Mounjaro overtook Ozempic in diabetes sales.
NVO's CagriSema failed to meet expectations in clinical trials.
Companies such as Viking Therapeutics, Altimmune, Roche, and Amgen are developing promising anti-obesity drugs, threatening the Novo Nordisk-Eli Lilly duopoly.
The company recently agreed to set a "maximum fair price" for Medicare under the Inflation Reduction Act.
As a result of the deal, the price of Wegovy for certain patient categories is also expected to drop to $149 per month, compared to the current starting price of $1,349. Such a sharp price reduction will directly impact revenue and profits.
Novo Nordisk's share of the US GLP-1 market fell to 43%, while Eli Lilly's grew to 57%.
To protect profitability, Maziar's new CEO, Mike Dusdar, initiated stringent cost-cutting measures, including a hiring freeze, layoffs, and a 23.8% reduction in R&D spending. While this may support cash flow in the short term, this strategy raises concerns about long-term innovation. Eight R&D projects were terminated, potentially slowing the market launch of promising next-generation drugs such as CagriSema and oral semaglutide.
NVO shares attempted a reversal around $60, but then this figure became a mirror level, and investors sold en masse from this price, which is certainly concerning. The chart shows volumes around $60. Be that as it may, the price is now below $50, and we can see the market trying to catch a low, trying to cling to any level. We're expecting a lower price.
While negative data on Eli Lilly's weight loss pill in August 2025 triggered a temporary optimistic rebound in NVO shares, it failed to reverse the overall downward trend caused by the company's deeper structural problems.
Now, in order:
Operating and Financial Results
Sales and operating profit growth forecasts for 2025 have been lowered twice; Q3 2025 results below expectations
Operating margin fell to 41.7% from 44.7% (YoY), gross margin decreased to 81.0% from 84.6%
Free cash flow declined 11% due to a sharp increase in capital expenditures
Competitive pressure:
Superiority of Eli Lilly products.
Zepbound (Eli Lilly) demonstrates greater effectiveness in weight loss (20.2% vs. 13.7% for Wegovy); Mounjaro overtook Ozempic in diabetes sales.
NVO's CagriSema failed to meet expectations in clinical trials.
Companies such as Viking Therapeutics, Altimmune, Roche, and Amgen are developing promising anti-obesity drugs, threatening the Novo Nordisk-Eli Lilly duopoly.
The company recently agreed to set a "maximum fair price" for Medicare under the Inflation Reduction Act.
As a result of the deal, the price of Wegovy for certain patient categories is also expected to drop to $149 per month, compared to the current starting price of $1,349. Such a sharp price reduction will directly impact revenue and profits.
Novo Nordisk's share of the US GLP-1 market fell to 43%, while Eli Lilly's grew to 57%.
To protect profitability, Maziar's new CEO, Mike Dusdar, initiated stringent cost-cutting measures, including a hiring freeze, layoffs, and a 23.8% reduction in R&D spending. While this may support cash flow in the short term, this strategy raises concerns about long-term innovation. Eight R&D projects were terminated, potentially slowing the market launch of promising next-generation drugs such as CagriSema and oral semaglutide.
NVO shares attempted a reversal around $60, but then this figure became a mirror level, and investors sold en masse from this price, which is certainly concerning. The chart shows volumes around $60. Be that as it may, the price is now below $50, and we can see the market trying to catch a low, trying to cling to any level. We're expecting a lower price.
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.